Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.
Date
2010-04-01
Journal Title
Journal ISSN
Volume Title
Repository Usage Stats
views
downloads
Citation Stats
Abstract
BACKGROUND: Conflicting results have been reported among studies of protease inhibitor (PI) use during pregnancy and preterm birth. Uncontrolled confounding by indication may explain some of the differences among studies. METHODS: In total, 777 human immunodeficiency virus (HIV)-infected pregnant women in a prospective cohort who were not receiving antiretroviral (ARV) treatment at conception were studied. Births <37 weeks gestation were reviewed, and deliveries due to spontaneous labor and/or rupture of membranes were identified. Risk of preterm birth and low birth weight (<2500 g) were evaluated by using multivariable logistic regression. RESULTS: Of the study population, 558 (72%) received combination ARV with PI during pregnancy, and a total of 130 preterm births were observed. In adjusted analyses, combination ARV with PI was not significantly associated with spontaneous preterm birth, compared to ARV without PI (odds ratio [OR], 1.22; 95% confidence interval [CI], 0.70-2.12). Sensitivity analyses that included women who received ARV prior to pregnancy also did not identify a significant association (OR, 1.34; 95% CI, 0.84-2.16). Low birth weight results were similar. CONCLUSIONS: No evidence of an association between use of combination ARV with PI during pregnancy and preterm birth was found. Our study supports current guidelines that promote consideration of combination ARV for all HIV-infected pregnant women.
Type
Department
Description
Provenance
Subjects
Citation
Permalink
Published Version (Please cite this version)
Publication Info
Patel, Kunjal, David E Shapiro, Susan B Brogly, Elizabeth G Livingston, Alice M Stek, Arlene D Bardeguez, Ruth E Tuomala, undefined P1025 team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group, et al. (2010). Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis, 201(7). pp. 1035–1044. 10.1086/651232 Retrieved from https://hdl.handle.net/10161/4142.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
Elizabeth Gresham Livingston
My academic and clinical expertise is in the area of HIV infection in pregnancy. I have participated in the ACTG (Aids Clinical Trial Group as well as PACTG/IMPAACT and the AACTG) since 1988. My specific interest is in complications of medical and surgical treatments for HIV-infected pregnant women. I have served as a principal investigator on ACTG 249 (DDI pharmacokinetics in pregnancy) and AACTG 5084 (Metabolic complications of protease inhibitors in pregnancy). I have a long time affiliation with the Duke Adult and Pediatric infectious disease clinics both for research and for clinical management of mothers and babies. Additionally I have clinical expertise in the care of diabetes in pregnancy, prenatal diagnosis and general high risk pregnancy care. I am an active member of the Division of Maternal Fetal Medicine and fully participate in our research efforts through recruitment of patients to trials within our division. I am involved in the education of medical students and residents.
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.